Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Matthias Birtel"'
Autor:
Khadijeh Alishah, Matthias Birtel, Elham Masoumi, Leila Jafarzadeh, Hamid Reza Mirzaee, Jamshid Hadjati, Ralf-Holger Voss, Mustafa Diken, Sedighe Asad
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-21 (2021)
Abstract Background CAR T-cell therapy has been recently unveiled as one of the most promising cancer therapies in hematological malignancies. However, solid tumors mount a profound line of defense to escape immunosurveillance by CAR T-cells. Among t
Externí odkaz:
https://doaj.org/article/8769556c873e4b6a8c4b997f63fda4a0
Autor:
Jan David Beck, Matthias Birtel, Erik Haefner, Isabell Sofia Keil, Daniel Reidenbach, Nadja Salomon, Ikra Gizem Yildiz, Mustafa Diken
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 4, Pp 808-815 (2020)
Externí odkaz:
https://doaj.org/article/8ffa44ef4fb248cd80f62da16596b3a3
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 12, Pp 2864-2873 (2018)
The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe’s largest meeting series of its kind, took place in Mainz, Germany from 15–17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among mor
Externí odkaz:
https://doaj.org/article/49e138e3d6924384a4905e2ba3d6d7eb
Autor:
Matthias Birtel, Ralf-Holger Voss, Katharina Reinhard, Benjamin Rengstl, Yasmina Ouchan, Kristina Michel, Nina Hayduk, Bodo Tillmann, René Becker, Martin Suchan, Matthias Theobald, Petra Oehm, Özlem Türeci, Ugur Sahin
Publikováno v:
Cancer Research Communications. 2:827-841
Chimeric antigen receptor (CAR) T cells are efficacious in patients with B-cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pair
Autor:
Ugur Sahin, Özlem Türeci, Petra Oehm, Matthias Theobald, Martin Suchan, René Becker, Bodo Tillmann, Nina Hayduk, Kristina Michel, Yasmina Ouchan, Benjamin Rengstl, Katharina Reinhard, Ralf-Holger Voss, Matthias Birtel
Supplementary Data and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::381bcc291c56fb9800786f04933391af
https://doi.org/10.1158/2767-9764.22545446
https://doi.org/10.1158/2767-9764.22545446
Autor:
Ugur Sahin, Özlem Türeci, Petra Oehm, Matthias Theobald, Martin Suchan, René Becker, Bodo Tillmann, Nina Hayduk, Kristina Michel, Yasmina Ouchan, Benjamin Rengstl, Katharina Reinhard, Ralf-Holger Voss, Matthias Birtel
Chimeric antigen receptor (CAR) T cells are efficacious in patients with B-cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pair
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc213ba4971e2ef943dc981633019540
https://doi.org/10.1158/2767-9764.c.6550946.v1
https://doi.org/10.1158/2767-9764.c.6550946.v1
Autor:
Nadja Salomon, Erik Haefner, Isabell Sofia Keil, Daniel Reidenbach, Ikra Gizem Yildiz, Jan Beck, Mustafa Diken, Matthias Birtel
Publikováno v:
Human Vaccines & Immunotherapeutics
The 17th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe`s cancer immunotherapy meeting, took place in Mainz, Germany from 21 to 23 May, 2019. Recent advancements in cance...
Publikováno v:
Human Vaccines & Immunotherapeutics
The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe’s largest meeting series of its kind, took place in Mainz, Germany from 15–17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among mor
Autor:
Elmar Christ, Martin Suchan, Kathrin Kuna, Yasmina Ouchan, Lena M. Kranz, Klaus Kühlcke, Oliver Klein, Arne Billmeier, Özlem Türeci, Kristina Michel, David Weber, Petra Oehm, Matthias Birtel, Katharina Reinhard, Thomas Bukur, Ugur Sahin, Benjamin Rengstl, Kathleen Hobohm, Karolina Anna Mroz, Mustafa Diken, Veronika Jahndel, Stefan Wöll, Nina Hayduk
Publikováno v:
Science (New York, N.Y.). 367(6476)
A one-two, CAR-T cell punch Chimeric antigen receptor (CAR)–T cells have been clinically effective in killing certain hematological malignancies, but achieving long-term patient responses for solid tumors remains a challenge. Reinhard et al. descri
Autor:
Sebastian Kreiter, Mathias Vormehr, Mustafa Diken, Christian Grunwitz, Matthias Birtel, Jutta Petschenka, Fulvia Vascotto, Lena M. Kranz, Ralf-Holger Voss, Lina Hilscher
Publikováno v:
Human Vaccines & Immunotherapeutics